FluoGuide (OM:FLUO) - 주가, 뉴스 및 분석

FLUO 주식 개요

임상 단계의 생명공학 회사인 FluoGuide A/S는 덴마크에서 암 형광 물질을 만들어 수술 결과를 개선하는 약물 개발에 주력하고 있습니다. 자세한 내용

FLUO 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 85.4% 에서 거래

위험 분석

수익이 1백만 달러 미만인 경우 ( DKK1M )

cash runway 경력이 1년 미만입니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( SEK474M )

+ 1 더 많은 위험

FluoGuide A/S 경쟁사

Hamlet BioPharma

NGM:HAMLET B

SEK 449.6m

Oncopeptides

OM:ONCO

SEK 324.9m

Isofol Medical

OM:ISOFOL

SEK 483.7m

Medivir

OM:MVIR

SEK 302.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 FluoGuide
과거 주가
현재 주가	SEK 34.85
52주 최고치	SEK 80.00
52주 최저치	SEK 32.00
베타	1.13
11개월 변경	-11.77%
3개월 변경 사항	-14.06%
1년 변경 사항	-52.26%
33년 변화	-61.49%
5년 변화	523.43%
IPO 이후 변화	529.06%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	FLUO	SE Biotechs	SE 마켓
7D	0%	-8.0%	-2.4%
1Y	-52.3%	12.6%	10.9%

수익률 대 산업: FLUO 지난 1년 동안 12.6 %를 반환한 Swedish Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: FLUO 지난 1년 동안 10.9 %를 반환한 Swedish 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is FLUO's price volatile compared to industry and market?
FLUO volatility
FLUO Average Weekly Movement	5.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

안정적인 주가: FLUO 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: FLUO 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2018	8	Morten Albrechtsen	fluoguide.com

덴마크의 임상 단계 생명공학 회사인 플루오가이드 A/S는 암을 형광으로 만들어 수술 결과를 개선하는 약물 개발에 주력하고 있습니다. 주요 제품 후보로는 고등급 신경교종 치료를 위한 임상 2a상 및 2b상, 폐암 및 두경부암 치료를 위한 임상 2상 시험이 진행 중인 FG001이 있습니다. 또한, 외과의가 수술 중 암과 정상 조직을 구별할 수 있도록 하는 새로운 uPAR 표적 발광 기술을 통해 전임상 단계에 있는 FG002를 개발 중입니다.

FluoGuide A/S 기본 사항 요약

FluoGuide 의 수익과 매출은 시가총액과 어떻게 비교하나요?
FLUO 기본 통계
시가총액	SEK 474.30m
수익(TTM)	-SEK 56.61m
수익(TTM)	SEK 1.90m

249.3x

P/S 비율

-8.4x

P/E 비율

FLUO 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
FLUO 손익 계산서(TTM)
수익	DKK 1.22m
수익 비용	DKK 0
총 이익	DKK 1.22m
기타 비용	DKK 37.65m
수익	-DKK 36.43m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

Nov 28, 2024

주당 순이익(EPS)	-2.68
총 마진	100.00%
순이익 마진	-2,976.06%
부채/자본 비율	0%

FLUO 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

FLUO 주식 개요

보상

위험 분석

FluoGuide A/S 경쟁사

NGM:HAMLET B

SEK 449.6m

OM:ONCO

SEK 324.9m

OM:ISOFOL

SEK 483.7m

OM:MVIR

SEK 302.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

FluoGuide A/S Announces Publication of Positive Phase II Clinical Data for FG001 in Patients with Head and Neck Cancer

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

FluoGuide A/S Submits Clinical Trial Application for Phase II Trial in Head and Neck Cancer

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Recent updates

FluoGuide A/S Announces Publication of Positive Phase II Clinical Data for FG001 in Patients with Head and Neck Cancer

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

FluoGuide A/S Submits Clinical Trial Application for Phase II Trial in Head and Neck Cancer

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132